Abstract: An agent for enhancing therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases is disclosed, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.
Abstract: A method of micro-incision ophthalmic surgery, comprising, in the order mentioned, the steps of: (1) injecting a first viscoelastic substance through an incision site which is lateral to corneal into an anterior chamber which is in an opposite part of the incision site with discharging aqueous humor; (2) injecting a second viscoelastic substance having higher surface tension than that of the first viscoelastic substance through the incision site into the remaining anterior chamber unfilled with the first viscoelastic substance; and (3) injecting a third viscoelastic substance having lower surface tension than that of the second viscoelastic substance through the incision site into an area of the anterior chamber which is filled with the first viscoelastic substance until the incision site is sealed with the already injected the second viscoelastic substance.
Abstract: The present disclosure provides methods and compositions for treating acute heart failure, by administering to a subject in need thereof a therapeutically effective amount of an AICA riboside analog or a pharmaceutically acceptable salt or prodrug thereof.
Abstract: A nutritional composition comprising a significant amount of arachidonic acid (ARA) is described. Such nutritional composition is particularly suitable for infants below the age of 3 years, preferably between birth and 12 months of life. The composition can be used to reduce the risk of developing overweight/obesity and/or insulin resistance later in life.
Abstract: A nutritional composition comprising a significant amount of arachidonic acid (ARA) is described. Such nutritional composition is particularly suitable for infants below the age of 3 years, preferably between birth and 12 months of life. The composition can be used to reduce the risk of developing overweight/obesity and/or insulin resistance later in life.
Abstract: A therapeutic agent for renal failure including, as an active ingredient, a 4,8-inter-m-phenylene prostaglandin I2 derivative, and also a method for treatment of renal failure using the same.
Abstract: An antiparasitic agent for fish includes an inhibitor of folate synthesis and/or an inhibitor of folate activation as the active substance(s). A combination preparation composed of an inhibitor of folate synthesis and an inhibitor of folate activation is disclosed. Sulfonamide is disclosed as suitable for the inhibitor of folate synthesis. A dihydrofolate reductase inhibitor, a folate antagonist are disclosed as suitable inhibitors of folate activation. The antiparasitic agent is able to exterminate fish parasites via oral administration. It is effective against fish parasites belonging to the ciliate group.
Abstract: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.
Abstract: Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylacetamide, polyethylene glycol and D5W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.
Abstract: The present invention provides methods of ameliorating or reducing the extent of ischemic injury, reperfusion injury, and myocardial infarction, by administering an inhibitor of histone deacetylase enzyme (HDAC) or an inhibitor of DNA methyltransferase enzyme (DNMT).
Type:
Grant
Filed:
December 16, 2013
Date of Patent:
July 19, 2016
Assignees:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, CHILDREN'S HOSPITAL OF PHILADELPHIA
Inventors:
Peter J. Gruber, Jonathan A. Epstein, Ibrahim Abdullah
Abstract: Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.
Type:
Grant
Filed:
May 21, 2012
Date of Patent:
February 16, 2016
Assignee:
AMIRA PHARMACEUTICALS, INC.
Inventors:
Jeffrey Roger Roppe, Timothy Andrew Parr, John Howard Hutchinson
Abstract: This document provides methods and materials related to treating orthostatic hypotension and/or postural tachycardia syndrome. For example, methods and materials for using a composition containing 3,4-diaminopyridine, 4-aminopyridine, or both to treat patients with orthostatic hypotension, postural tachycardia syndrome, or both orthostatic hypotension and postural tachycardia syndrome are provided.
Type:
Grant
Filed:
September 3, 2010
Date of Patent:
October 13, 2015
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages or injuries caused by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (I). The active ingredient compound is capable of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order.
Abstract: The present invention is directed to water-in-oil (W/O) emulsion compositions containing gellan gum which provide an enhanced rate of release of active ingredients for delivery to the skin or mucosa.
Type:
Grant
Filed:
October 5, 2011
Date of Patent:
September 15, 2015
Assignee:
DFB Technology, Ltd.
Inventors:
Duncan T. Aust, David P. Jones, Aleksa V. Jovanovic, Vitthal Kulkarni, Promod Kumar, Lei Shi
Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type 1), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp, infections, especially including Entamoeba histolytica.
Abstract: FGF receptor agonist compounds corresponding to the general formula: M1-L-M2 are disclosed in which M1 and M2, which may be identical or different, each represent, independently of one another, a monomer unit M, and L represents a linker group, wherein the monomer unit is of the general formula I.
Abstract: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
Type:
Grant
Filed:
March 19, 2013
Date of Patent:
August 18, 2015
Assignee:
SANOFI
Inventors:
Davide Radzik, Martin Van Eickels, Nacera Hamdani, Christophe Gaudin
Abstract: The present invention relates to a liquid pharmaceutical composition containing an N-phenylpyrazole derivative as active ingredient and alpha-(tetrahydrofuranyl)-omega-hydroxypoly(oxy-1,2-ethanediyl) as solvent for the treatment and/or prevention of infestations with fleas in domestic animals.
Abstract: Agonists of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.
Type:
Grant
Filed:
September 30, 2010
Date of Patent:
August 11, 2015
Assignee:
THE UNIVERSITY OF CONNECTICUT
Inventors:
Timothy Hla, Teresa Sanchez, Kevin Patrick Claffey, Ji-Hye Paik